- The company now partners with 99 commercial sites as of the end of 2025, a 1,880% year-on-year surge.
- Similarly, Firefly has completed over 10,800 EEG/ERP brain scans in 2025, a 3,227% YoY increase.
- The company uses NVIDIA L40S GPU accelerators to power EEG/ERP processing.
Firefly Neuroscience, Inc. (AIFF) on Wednesday reported a notable surge in its operations, including an expansion of its commercial presence and brain scan activity.
The company emphasized that the surge in data, combined with advanced supercomputing resources, can accelerate AI-driven biomarker discovery.
Expansion and Data Growth
Firefly said it has achieved more than a 20-fold increase in its commercial footprint and a 33-fold jump in EEG/ERP brain scan volumes over the past year.
The company now partners with 99 commercial sites, collectively completing over 10,800 EEG/ERP brain scans by the end of 2025, a breakout surge of 1,880% and 3,227% respectively, from 2024 figures.
“With an exponentially growing foundation of clean data, and by deploying NVIDIA L40S GPU acceleration to power next-generation EEG/ERP processing, the company believes that it is poised to make additional new breakthroughs in cognitive brain biomarker discovery, and to fulfill its goal of building and launching the world’s first EEG/ERP-based foundation model of the human brain.”
-Greg Lipschitz, CEO, Firefly
Following the update, Firefly Neuroscience stock traded over 45% in Wednesday’s premarket. On Stocktwits, retail sentiment around the stock jumped to ‘extremely bullish’ from ‘bullish’ territory the previous day. Message volume shifted to ‘extremely high’ from ‘high’ levels in 24 hours.
AI-Powered Brain Analysis
Firefly uses artificial intelligence to better understand how the brain works. It builds tools that help doctors and researchers study brain activity more clearly and help in diagnosing and tracking conditions such as depression, dementia, anxiety, concussions, and ADHD.
The company has created a large collection of brain scan data, with more than 191,000 EEG and ERP scans.
AIFF stock has declined by more than 72% over the last 12 months.
For updates and corrections, email newsroom[at]stocktwits[dot]com.